EP1833975A2 - Expression regulee de transgenes dans le systeme nerveux central de mammiferes - Google Patents
Expression regulee de transgenes dans le systeme nerveux central de mammiferesInfo
- Publication number
- EP1833975A2 EP1833975A2 EP05849656A EP05849656A EP1833975A2 EP 1833975 A2 EP1833975 A2 EP 1833975A2 EP 05849656 A EP05849656 A EP 05849656A EP 05849656 A EP05849656 A EP 05849656A EP 1833975 A2 EP1833975 A2 EP 1833975A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- rapamycin
- vector
- expression
- transgene
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 131
- 108700019146 Transgenes Proteins 0.000 title claims abstract description 112
- 230000001105 regulatory effect Effects 0.000 title abstract description 41
- 210000003169 central nervous system Anatomy 0.000 title abstract description 12
- 241000124008 Mammalia Species 0.000 title abstract description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 144
- 239000013598 vector Substances 0.000 claims abstract description 120
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 110
- 229960002930 sirolimus Drugs 0.000 claims abstract description 110
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 45
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 45
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 37
- 239000013608 rAAV vector Substances 0.000 claims abstract description 15
- 238000013518 transcription Methods 0.000 claims abstract description 13
- 230000035897 transcription Effects 0.000 claims abstract description 13
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 7
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 38
- 239000013607 AAV vector Substances 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims description 2
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 108
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 abstract description 58
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 abstract description 55
- 210000004556 brain Anatomy 0.000 abstract description 28
- 239000000411 inducer Substances 0.000 abstract description 20
- 230000004568 DNA-binding Effects 0.000 abstract description 19
- 230000004913 activation Effects 0.000 abstract description 17
- 230000027455 binding Effects 0.000 abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 10
- 229920001184 polypeptide Polymers 0.000 abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 239000003623 enhancer Substances 0.000 abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 5
- 150000003384 small molecules Chemical class 0.000 abstract description 3
- 102000024452 GDNF Human genes 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 96
- 101000884046 Homo sapiens Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 64
- 102000047109 human DDC Human genes 0.000 description 59
- 241000700159 Rattus Species 0.000 description 42
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 34
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 30
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 25
- 238000001415 gene therapy Methods 0.000 description 23
- 238000010361 transduction Methods 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 230000026683 transduction Effects 0.000 description 21
- 230000033228 biological regulation Effects 0.000 description 20
- 210000002845 virion Anatomy 0.000 description 20
- 230000006870 function Effects 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 229960003638 dopamine Drugs 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 238000001802 infusion Methods 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 230000001506 immunosuppresive effect Effects 0.000 description 13
- 210000001577 neostriatum Anatomy 0.000 description 13
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 102000052654 human GDNF Human genes 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000003523 substantia nigra Anatomy 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 241000701022 Cytomegalovirus Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 230000008488 polyadenylation Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 8
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000001190 Q-PCR Methods 0.000 description 5
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 5
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000002637 putamen Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000009331 Homeodomain Proteins Human genes 0.000 description 3
- 108010048671 Homeodomain Proteins Proteins 0.000 description 3
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 3
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 101000884049 Rattus norvegicus Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 3
- 206010071390 Resting tremor Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- 210000001159 caudate nucleus Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000001653 corpus striatum Anatomy 0.000 description 3
- 108091007930 cytoplasmic receptors Proteins 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010245 stereological analysis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- -1 7-methylindolyl Chemical class 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 241001573498 Compacta Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 101150082979 gdnf gene Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- KGWPHCDTOLQQEP-UHFFFAOYSA-N 7-methylindole Chemical group CC1=CC=CC2=C1NC=C2 KGWPHCDTOLQQEP-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102100026376 Artemin Human genes 0.000 description 1
- 101710205806 Artemin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010001589 Glial Cell Line-Derived Neurotrophic Factors Proteins 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100021584 Neurturin Human genes 0.000 description 1
- 108010015406 Neurturin Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100036660 Persephin Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 108010009400 levodopa receptor Proteins 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 description 1
- 229960001794 melevodopa Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010070453 persephin Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Definitions
- the present invention relates to regulation of genes introduced by gene therapy, specifically regulation of the expression of transgenes transduced into the central nervous system (CNS) of mammals.
- CNS central nervous system
- genes are under-expressed, or when the gene product itself is defective, the absence of the corresponding functional gene product may be treated by delivery of the missing gene product to the subject. Delivery of proteins, however, is often difficult and confers benefit for only a limited time, meaning that protein must be re-administered repeatedly on a regular basis, perhaps indefinitely, as in the case of chronic illnesses. Repeated administration can be expensive, inconvenient, and may suffer due to poor patient compliance.
- the level of gene product may vary dramatically between the time just after administration of one dose and the time just before the administration of the next dose. This variability in level is particularly problematic for therapeutic agents with poor pharmacokinetics (e.g. a short half- life) or a low therapeutic index.
- Gene therapy can be used to deliver a gene, rather than the gene product, to a cell exhibiting suboptimal expression of that gene.
- gene therapy can also be used to deliver other genes that may have a beneficial effect when expressed in a target cell, such as cytokines, hormones, antibodies or genetically modified proteins.
- the gene delivered by gene therapy is referred to herein as a transgene.
- transgene When a transgene is stably expressed within the target cell, gene therapy has the potential to deliver a steady level of a gene product indefinitely. Gene therapy need only be performed once, or at least infrequently, compared to the repeated delivery of
- Gene therapy is particularly preferred as a means for delivering
- Viral vectors have been developed to assist in efficient delivery of transgenes to target
- transduction a process referred to herein as transduction.
- AAV adeno-associated virus
- AAV Dependovirus
- AAV dividing cells makes AAV a particularly good choice for transduction of CNS tissue, e.g.
- AAV has not been
- AAV is stable at a wide range of physical
- the AAV genome is a linear, single-stranded DNA molecule approximately 4681
- the AAV genome generally comprises an internal non-repeating genome flanked on each end by inverted terminal repeats (ITRs).
- ITRs inverted terminal repeats
- the ITRs act as origins of DNA replication and as packaging
- the internal non-repeated portion of the genome includes two main open reading
- rep and cap genes code for the AAV replication (rep) and capsid (cap) genes.
- the rep and cap genes code for the AAV replication (rep) and capsid (cap) genes.
- a family of at least four viral proteins is expressed from the AAV rep region; Rep 78, Rep 68, Rep 52, and Rep 40, named according to their apparent molecular weight.
- AAV cap region encodes at least three proteins; VPl, VP2, and VP3.
- AAV is a helper-dependent virus; that is, it generally requires co-infection with a
- helper virus e.g., adenovirus, herpesvirus or vaccinia
- helper virus in order to form AAV virions, hi the absence of co-infection with a helper virus, AAV establishes a latent state in which the viral
- helper virus infect cells from different species, the helper virus must be of the same species as the host
- human AAV will replicate in canine cells co-infected with a canine
- AAV vectors have been engineered to deliver genes of interest by deleting the internal
- non-repeating portion of the AAV genome i.e., rep and cap
- transgene between the ITRs.
- the transgene may be linked to a heterologous
- Termination signals such as polyadenylation sites, can also be included.
- a suitable producer cell line is transfected with an AAV expression vector containing a
- Helper functions are those functions normally
- AAV-encoded genes e.g. rep and cap
- accessory functions are those functions normally provided by helper- virus when wild-type AAV (wtAAV) replicates in
- helper virus e.g. adenovirus
- wtAAV must be supplied separately because they are removed in construction of rAAV
- rAAV recombinant AAV virion
- the rAAV stock so prepared can then be used to introduce the transgene into target
- helper virus Because the subject's cells lack the rep and cap genes and the accessory
- rAAV vectors are replication defective in the target cell; that is, they cannot
- wtAAV cannot be formed in the subject's cells.
- One such system based on induction by rapamycin (referred to herein as the
- dimerizer system involves formation of a functional transcription factor from two
- Rapamycin is an orally bioavailable small-molecule drug, closely related to
- the dimerizer system has been adapted for use with viral vectors to
- the dimerizer system is also a component of the ARGENT Transcription Technology platform of
- the dimerizer system has the advantage of being fully humanized, in that the
- Parkinson's disease is an example of a disease that may be amenable to gene
- PD is the second most common neurodegenerative segment of the central nervous system.
- dopaminergic neurons in the substantia nigra of the basal ganglia region of the brain.
- Dopamine is synthesized in the terminal nerve endings of the dopaminergic neurons
- nerves project into the corpus striatum, specifically innervating the putamen and the caudate
- TH hydroxylase
- GCH guanosine triphosphate cyclohydrolase I
- aromatic L-amino amino acid hydroxylase
- AADC acid decarboxylase
- L-dopa L-dihydroxyphenylalanine
- AADC removes the terminal carboxyl group of L-dopa to produce dopamine.
- Treatment of PD currently involves oral administration of L-dopa, often in
- dopa are required for therapeutic efficacy, but this often results in increased side effects.
- One gene therapy-based approach to treatment of PD is to supply genes encoding one
- AADC enzymes involved in dopamine biosynthesis
- AADC restores the effectiveness of treatment of L-dopa.
- AAV-derived vectors and methods of treatment of PD by delivery and expression of AADC in the brain of mammalian subjects are described in U.S. Pat. App. Publication No. 2002/0172664, the disclosure of which is
- Parkinson's disease is characterized by the progressive loss of dopaminergic
- Another gene therapy-based approach to treatment of PD is to deliver genes that block
- GDNF GDNF
- AAV-derived vectors and methods of treatment of PD by delivery and expression of GDNF in the brain of mammalian subjects are described in U.S. Pat. App. Publication No.
- transgene expression be regulated to desirable levels within each transfected cell
- dopamine can in principle be controlled by exogenous delivery of its precursor L-dopa,
- regulation maybe beneficial to accurately control the dose of enzyme delivered, or to effect
- neurotrophic factors such as GDNF
- over-expression could have deleterious effects
- CNS e.g. the brain
- vectors enabling such regulation.
- the regulatory system preferably, the regulatory system
- the optimal system would also comprise functional
- the present invention provides vectors, methods and kits for AAV-mediated gene therapy in which expression of the
- transgene within the target cells in the nervous system can be regulated using an inducer.
- the invention relates to recombinant AAV (rAAV) vectors in which
- transgene expression can be regulated after the transgene has been transduced into the CNS
- regulation is effected using a transcription factor comprising two
- polypeptide components said transcription factor only being active when the two components
- the two polypeptides comprise a DNA binding domain fusion
- An exemplary DNA binding domain fusion comprises two DNA binding domains from the human transcription factor Zif268, a homeodomain derived
- exemplary activation domain fusion comprises the rapamycin binding domain of human
- FRAP fused to the transcriptional activation domain derived from the p65 subunit of NFKB.
- a first rAAV vector comprises the transgene and a second rAAV
- vector comprises the sequence of the transcription factor components.
- regulation is accomplished by administration of an inducer, hi
- the inducer is a dimerizer, such as rapamycin or a non-
- immunosuppressive analog thereof e.g. AP21967.
- the invention relates to methods of treatment of subjects with rAAV
- transgene expression can be regulated after the transgene has been
- treatment involves administration of an inducer, for example a dimerizer, such as rapamycin
- a non-immunosuppressive analog thereof e.g. AP21967.
- the invention relates to kits for constructing the vectors, or
- the kit comprises a first rAAV
- the kit further comprises a second rAAV vector encoding a transcription factor that can regulate expression from the transgene cloned into the first rAAV vector.
- the kit comprises an inducer, for example a dimerizer such as
- rapamycin or a non-immunosuppressive analog thereof e.g. AP21967.
- the invention involves treatment of a human neurodegenerative
- Parkinson's disease PD
- the regulated transgene is AADC or GDNF, although in
- the regulated transgene can be any gene whose expression in the target tissue is
- FIG. IA is a diagram of a rAAV vector encoding the activation and DNA binding
- AAV-CMV-TF a transcription factor for regulation of transgene expression
- transcription factor vectors Such vectors are referred to herein as transcription factor vectors.
- FIG. IB is a diagram of a recombinant AAV vector encoding hAADC (AAV-Z12-
- hAADC hAADC
- Such vectors are referred to herein as expression vectors.
- FIG. 1C is a diagram of a recombinant AAV vector encoding hAADC (AAV-CMV- hAADC2), expression of which is driven by the constitutive CMV promoter.
- FIG. 2 shows the results of experiments in which D7-4 cells are transduced with
- OD values refer to the relative AADC expression (as measured by OD 4 O 5 in an AADC expression ELISA) calculated using a
- FIG. 3 is a timeline for experiments in which the rotational response to L-dopa is
- FIG. 4 shows the rotational response to 5 mg/kg L-dopa in 6-OHDA lesioned rats
- Rats are infused with either excipient alone (control) or with vectors encoding regulatable hAADC and the corresponding transcription factors. Data are not presented for
- FIG. 3 are represented as a single arrow in FIG. 4.
- FIG. 5 A shows the results of immunohistochemistry for AADC within the striatum of
- the scale bar represents 75 ⁇ m.
- FIG. 5B show results of an experiment similar to that shown in FIG. 5 A but in which the rat is not treated with rapamycin.
- FIG. 6 shows the results of immunohistochemistry for AADC in whole mounted
- A vector-infused (+) rap
- B vector-infused (-) rap
- C excipient-infused (+) rap.
- rats were infused with either excipient alone (FIG. 6C), or with vectors
- FIGS. 6A and 6C Animals in FIGS. 6A and 6C were subsequently treated with rapamycin (as shown in FIG. 3)
- the left hemisphere is the site of both 6-OHDA lesion and intrastriatal vector (or excipient) infusions, and the right hemisphere shows endogenous
- FIG. 7 shows the expression of AADC at 7 weeks post-infusion, as measured by
- top panels are images of the AADC and ⁇ -actin bands observed in gel electrophoresis of
- the bar graph shows the average integrated image intensities
- FIG. 8A is a diagram of an rAAV vector (AAV-TF-Z8-hGDNF) comprising a
- hGDNF expression can be regulated by addition of rapamycin or derivatives thereof.
- FIG. 8B is a diagram of a vector similar to that shown in FIG. 8 A, except that
- FIG. 8C is a diagram of a recombinant AAV vector encoding hGDNF, expression of
- FIG. 9 shows GDNF expression, in picograms (pg), for HeLa D7-4 cells transiently
- a regulated TF-GDNF plasmid AAV-TF-Z8-hGDNF
- a regulated TF-GDNF plasmid AAV-TF-Z8-hGDNF
- a vector includes a mixture of two or more such vectors, and the like.
- transgene refers to any gene to be delivered to a target cell
- Transgenes may direct production of messenger RNAs encoding proteins, or they may encode biologically active RNA molecules, such as antisense, ribozyme, triplex-forming,
- RNAi or other RNA sequences are examples of RNA sequences.
- a "regulatable transgene,” as used herein, is a gene whose expression can be altered
- transgene expression provides pharmacologic control of the level of transgene
- “Expression cassette” refers to an assembly which is capable of directing the
- the expression cassette includes a
- promoter or promoter/enhancer which is operably linked to (so as to direct transcription of)
- sequence(s) or gene(s) of interest and often includes a polyadenylation sequence as well.
- adeno-associated virus construct contained within an adeno-associated virus construct.
- Recombinant as used herein to describe a nucleic acid molecule means a
- polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue
- polypeptide means a polypeptide produced by expression of a recombinant polynucleotide, hi
- the gene of interest is cloned and then expressed in transformed organisms, as
- the host organism expresses the foreign gene to produce the protein
- a "coding sequence” or a sequence which "encodes” a selected polypeptide is a
- nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of
- sequences (or "control elements").
- the boundaries of the coding sequence can be determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy)
- a coding sequence can include, but is not limited to, cDNA from viral, procaryotic
- a transcription termination sequence may be located 3' to the
- control elements include, but are not limited to, transcription promoters,
- transcription enhancer elements transcription termination signals, polyadenylation sequences
- nucleic acid includes DNA and RNA, and also their analogues, such as
- PNA nucleic acids
- transfection is used to refer to the uptake of foreign DNA by a cell.
- a cell has been "transfected” when exogenous DNA has been introduced inside the cell membrane.
- DNA moieties such as a plasmid vector and other nucleic acids
- transduction denotes the delivery of a DNA molecule to a recipient cell either in vivo or in vitro, via a vector, such as a recombinant adeno-associated virus vector.
- a vector such as a recombinant adeno-associated virus vector.
- heterologous as it relates to nucleic acid sequences such as gene sequences
- control sequences denotes sequences that are not normally joined together, and/or are not
- nucleic acid normally associated with a particular cell.
- a heterologous region of a nucleic acid normally associated with a particular cell.
- construct or a vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature.
- a nucleic acid molecule that is not found in association with the other molecule in nature.
- heterologous region of a nucleic acid construct could include a coding sequence flanked by
- heterologous coding sequence is a construct where the coding sequence itself is not found in
- control elements refers collectively to promoter regions, polyadenylation
- IVS internal ribosome entry sites
- enhancers enhancers
- sequence is capable of being replicated, transcribed and translated in an appropriate host cell.
- promoter region is used herein in its ordinary sense to refer to a nucleotide
- RNA polymerase from a gene which is capable of binding RNA polymerase and initiating transcription of a
- “Operably linked” refers to an arrangement of elements wherein the components so
- control elements operably linked to a coding sequence are capable of effecting the expression of the coding
- control elements need not be contiguous with the coding sequence, so long as
- transcribed sequences can be present between a promoter sequence and the coding sequence
- promoter sequence can still be considered "operably linked" to the coding sequence.
- isolated when referring to a nucleotide sequence, is meant that the indicated
- an "isolated nucleic acid molecule which encodes a particular polypeptide” refers
- nucleic acid molecule which is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include some additional bases
- a "vector” is capable of transferring nucleic acid sequences to target cells (e.g., viral
- vectors typically, vector constructs, non-viral vectors, particulate carriers, and liposomes.
- vector construct typically, vector construct
- expression vector means any nucleic acid construct capable of directing the expression of a nucleic acid of interest and which can transfer nucleic acid
- sequences to target cells include cloning and expression vehicles, as well as
- subject any member of the subphylum chordata, including, without
- humans and other primates including non-human primates such as chimpanzees
- farm animals such as cattle, sheep, pigs, goats and
- mice as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as
- regulatable transcription factor and/or transgene is intended an amount that when the AAV
- ameliorates symptoms or prevents progression of a neurological disorder ameliorates symptoms or prevents progression of a neurological disorder.
- a therapeutic agent e.g., AADC, GDNF
- Parkinson's disease may ameliorate symptoms, e.g., improve motor function or reduce
- the present invention provides vector constructs, methods and kits for regulation of
- transduction of a regulatable transgene in a target cell are provided on a plurality of separate
- Examples 1 and 2 demonstrate the construction and use of a dual-vector embodiment of the present invention. In another embodiment, a single
- recombinant AAV vector carries all the sequences necessary for transduction of a regulatable
- Example 3 demonstrates the construction and use of one such
- a regulatable form of the AADC gene is delivered to target cells.
- Examples 1 and 2 demonstrate delivery of a regulatable form of the AADC gene, hi another
- a regulatable form of the GDNF gene is delivered to target cells.
- transgene refers to any gene to be delivered to a target cell
- Transgenes may direct production of messenger RNAs encoding proteins, or they
- RNA molecules may encode biologically active RNA molecules, such as antisense, ribozyme, triplex-forming,
- a regulatable transgene is a gene whose expression can be altered by
- transgene expression provides pharmacologic control of the level of transgene
- the inducer is a small molecule drug.
- molecule drug is rapamycin.
- the regulatable gene expression system of the present invention is operable to control the expression of the present invention
- rapamycin analog to produce an active transcription factor complex that specifically activates
- AP21967 (molecular mass 1017.4 Da) is the 7-methylindolyl analog of Compound 69
- AP21967 is identical to Compound 71 of the '595 patent except that AP21967 has a 7-methyl group on the indole ring.
- Rapamycin analogs that do not interact with the endogenous FRAP in the
- FRAP forms of FRAP can be created that retain the ability to bind to these non-immunosuppressive
- rapamycin analogs for use in the FRB portion of the activation domain fusion protein of the
- dimerizer system See, e.g., Pollock et al. (2000).
- transgene is made dependent on reconstitution of a functional transcription factor (TF) by the
- transcription factor AAV vector is used to deliver the DNA binding domain and the activation
- an expression AAV vector is used to deliver the
- hAADC transgene under the control of a regulatable promoter.
- Example 1 The dimerizer used in Example 1, AP21967, is a non-reacted dimerizer
- promoter at 25 nM AP21967 is roughly half the level from hAADC under control of the
- AAV-CMV-hAADC2 constitutive CMV promoter (AAV-CMV-hAADC2) (FIG. 1C, and described at Sanftner et al.
- OHDA OHDA rat model of Parkinson's disease
- a surgical model of striatal denervation as
- Parkinsonian rats are transduced with both AAV-CMV-TF and AAV-Z 12-hAADC and their
- Rapamycin is used in the in vivo experiments, rather than AP21967 as was used in
- the dimerizer rapamycin has many favorable properties for use as an inducer in human gene
- immunosuppressive analogs of rapamycin such as AP21967, may be superior inducers of
- transgene expression particularly in treatment of human subjects.
- AP21967 in animals and human subjects in vivo may be determined by standard experimental
- L-dopa and rapamycin results in behavioral effects in 6-OHDA-lesioned rats consistent with production of significant levels of dopamine. As illustrated in FIG. 4, treatment with
- rapamycin reversibly increases hAADC expression in the lesioned striatum, as evidenced by
- FIG. 5A demonstrates strong immunohistochemical staining for AADC, and thus
- FIG. 5B shows only very low level AADC
- FIGS. 6A-6C present low resolution images of whole mounted brain sections
- Table 1 presents the results of transgene-derived immunostaining
- Rapamycin-induced animals show approximately twice the anterior-to-
- FIG. 7 Western blot analysis of hAADC enzyme levels after gel electrophoresis of striatal
- induction is not enough to elicit a behavioral response to a sub-therapeutic dose of L-dopa
- induction in vivo may be determined by experimentation on a case-by-case basis, as is
- Dosage may be adjusted by trial and error based on
- exemplary dosages might range from
- 0.01 to 50 mg/kg preferably 0.1 to 10 mg/kg, for example 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 0.9,
- Recombinant AAV vectors can be surgically introduced at various locations in the
- the basal ganglia are groups of neurons positioned subcortically.
- the caudate nucleus and the caudate nucleus include the caudate nucleus, putamen, and globus pallidus.
- the caudate nucleus and the caudate nucleus include the caudate nucleus, putamen, and globus pallidus.
- putamen together form the corpus striatum (or simply striatum).
- the caudate and putamen are reciprocally interconnected with the substantia nigra, which consists of the substantia
- SNpc nigra pars compacta
- SNpc nigra pars compacta
- dopamine synthesis can be any enzymes in the dopamine biosynthetic pathway, such as AADC, dopamine synthesis.
- Corpus striatal cells can be transduced using a variety of techniques known in the art.
- stereotaxic injection is a common surgical technique used by neurosurgeons to create stereotaxic injection.
- Direct injection can also be employed; if using this technique, anatomical maps derived from CT, PET, or MRI scans can be used by the
- hAADC in the expression vector.
- expression vectors like the one illustrated at FIG. IB e.g. ITR regions, promoter,
- transgene sequences in the expression vector are transcription factor binding sequences, etc.
- any desired transgene can be delivered using the rAAV expression- vector constructs of a dual- vector embodiment of the present invention.
- shorter ITR, promoter or transcription factor binding regions may be constructed to enable
- hAADC transgene can be regulated in human cells in culture, and in rat neurons in vivo, using
- FIG 8 A A diagram of a regulated rAAV hGDNF expression vector is provided at FIG 8 A,
- FIG. 8C a diagram of a control vector with constitutive (unregulated) hGDNF expression is provided as FIG. 8C.
- FIG. 8B shows an alternative design for a regulated GDNF expression
- Plasmid vectors are transiently transfected into HEK-
- FIG. 9 The data show rapamycin-dose-responsive expression of GDNF in cells transfected
- TF-GDNF plasmid which refers to pAAV-TF-Z8-hGDNF
- CMV-GDNF plasmid the constitutively expressed GDNF
- GDNF expression from pCMV-GDNF is not increased by addition of rapamycin.
- Example 3 The experiment described in Example 3 demonstrates that a single- vector regulatable
- AAV-GDNF construct can be constructed that in which GDNF expression can be regulated in human cells in culture simply by addition of the small molecule inducer rapamycin.
- Treatment with a single vector has the advantage of requiring only one transduction
- transcription factor fusion proteins and regulatory elements used in the rAAV vector are used in the rAAV vector.
- transgene (GDNF) sequence is
- transgene sequences e.g. up to 850 or
- transgenes may comprise active sub-fragments of desirable genes,
- rAAV virions rather than full-length genes, to facilitate single- vector delivery.
- units of dose in vector genomes/per kilogram of body weight may depend on several
- the proper dose of rAAV used to effect transduction in a mammal may range from
- GDNF are presented as exemplary transgenes in the examples herein, the specific transgene to be delivered is not a limiting aspect of the present invention.
- genes that might be expected to provide a beneficial (e.g. therapeutic) effect may be
- sequence is short enough to fit into an AAV vector construct that can be
- TH tyrosine hydroxylase
- neurotrophins include neurotrophins, including GDNF (OMEVI 600837, Genbank Accession No. AX713049, L19063) and other members of the GDNF protein family, such as artemin (OMIM 603886, Genbank Accession No. AF109401), neurturin (OMM 602018,
- transgenes include IL-IO (OMM 124092, Genbank Accession No. M57627).
- OMIM numbers refer to the Online Mendelian Inheritance in Man database
- Genbank accession numbers are provided for representative complete cDNA
- transgenes include other sequences reported for the gene in Genbank, full-length and
- Transgenes also include genes for treatment of other neurodegenerative diseases, such as Alzheimer's, diabetes, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, such as
- Alzheimer's disease Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Canavan disease, cerebral ischemia, progressive supranuclear palsy, Lewy body
- corticobasal degeneration multiple system atrophy and retinal degeneration (e.g. macular
- the inducer is preferably selected from among compounds that can be delivered to a
- the inducer is able to cross the blood-brain barrier.
- the inducer is a dimerizer, for example rapamycin or
- the inducer is delivered parenterally, e.g. by subcutaneous,
- the inducer is any substance that is administered to the patient intramuscular, intraocular or intravenous injection.
- the inducer is any substance that is administered to the patient.
- nasal delivery nasal spray
- aerosol/pulmonary delivery inhaler
- ocular delivery eye drops
- Inducer may also be delivered continuously or semi-
- minipump a mechanical infusion pump or a controlled release pharmaceutical composition.
- Stocks of rAAV vectors according to the present invention may be prepared using any
- Wild-type AAV and helper viruses can be used to provide the necessary replicative functions for producing rAAV
- helper function genes e.g. pHLP 19
- the accessory function genes e.g. pladeno 5
- both in the case of the triple transduction are the accessory function genes (e.g. pladeno 5), or both in the case of the triple transduction
- rAAV virions are formulated into pharmaceutical compositions
- excipients include any pharmaceutical agent that does not itself
- liquids such as water, saline, glycerol and ethanol.
- hydrochlorides such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like.
- auxiliary substances such as wetting or emulsifying agents, pH buffering substances, and the
- rAAV virions of the present invention are supplied as
- compositions comprising excipients that enhance viral stability during
- excipients exhibit low toxicity in the
- target tissue e.g. the CNS.
- virions can be stored and supplied in buffer
- kits for construction of AAV vectors are provided.
- one or more vectors for regulated expression of transgenes.
- vectors similar to those shown in FIGS. IB, 8A or 8B are identical to those shown in FIGS. IB, 8A or 8B.
- FIG. IB are useful in dual- vector methods, whereas vectors similar to those shown in
- FIGS. 8 A and 8B are useful in single- vector methods of the present invention.
- a user of a kit of the present invention can clone a gene or gene fragment of interest into an expression
- Kits including expression vectors for use in dual- vector methods may also include a
- transcription factor vector substantially similar to that shown in FIG. IA.
- Kits may optionally include rapamycin or an analog thereof.
- Kits may also optionally include plasmids for use in preparing rAAV virion stocks,
- Kits may also contain instructions for use.
- gene therapy vectors, methods and kits of the present invention are administered to a subject afflicted with a disease, such as Parkinson's disease, to provide a disease.
- a disease such as Parkinson's disease
- therapeutic effect refers to a level of expression of one or more transgenes sufficient to alter a component of a disease (or disorder) toward a
- a therapeutic effect can be an
- a reduction in resting tremor can also be a
- PPRS Primate Parkinsonism Rating Scale
- CRS Clinical Rating Score
- bradykinesia bradykinesia, hypokinesia, and muscular rigidity.
- the PPRS system is described in Langston
- FIG. IA is a diagram of AAV-CMV-TF, in which
- CMV cytomegalovirus
- domain fusion protein contains the rapamycin binding domain (FRB*) of human FRAP fused
- FRB domain used in this embodiment (FRBT 2 O9SL) 3 and illustrated in FIG. IA (FRB*), carries a T to L mutation at position 2098 when compared to the wild-type FRB
- FRB T2098L can be dimerized to the DNA binding domain fusion using either AP21967 or rapamycin.
- the internal ribosome entry sequence (IRES) is derived from encephalomyocarditis
- the DNA binding domain fusion protein contains two DNA binding domains from the
- FIG. IB is a
- ITR inverted terminal repeat
- hAADC hAADC coding sequence
- human growth
- HeLa D7-4 cells with a 1:1 ratio AAV-CMV-TF and AAV-Z12-hAADC, and subsequently
- AAV-CMV-TF transcription factor vector alone
- hAADC vector AAV-CMV-hAADC2
- hAADC vector (AAV-Z12-hAADC) but lacking the transcription factor vector.
- AAV-CMV-TF has been described previously (AAV-CMV-TF INc, Auricchio et al.
- AAV-Z12-hAADC is created by replacing the CMV enhancer
- Recombinant AAV vectors (serotype 2) are generated by triple transfection of
- HEK-293 ATCC Accession No. CRLl 573 cells and purified by CsCl density gradient
- rAAV are microfluidized and filtered through 0.2- ⁇ m filters.
- Vector is purified from the
- PAGE gels. Titer is determined by Q-PCR analysis of vector genomes.
- the expression ELISA measures the expression of hAADC protein in permeabilized
- HeLa D7-4 cells using an antibody against hAADC. HeLa D7-4 cells are transduced with
- Cells are seeded in a 96-well plate 24 hr before transduction. Cells are transduced with an MOI of 10 4 vg/cell (of each vector when multiple vectors are used) in 100
- ELISA is performed on transduced cells 48 h post-transduction. Briefly, media are
- the primary antibody (AB 136 rabbit anti-
- hAADC, Chemicon, 1 :1000 is diluted in wash buffer (1% goat serum, 0.5% Triton X 100 in
- FIGS. IA and IB are also tested in vivo in the 6-
- hydroxydopamine (6-OHDA) rat model of Parkinson's disease as follows. Rapamycin is used instead of AP21667 as dimerizer in Example 2 because of its higher potency and known pharmacokinetics. Rapamycin has a half-life of approximately 1Oh in vivo with rapid
- excipient-infused control group excipient-infused (+)
- rapamycin treatment a vector-infused (-) rapamycin treatment control group, and a vector-
- the vector-infused (-) rapamycin group serves as a control for hAADC gene expression in the absence of rapamycin, i.e. to determine whether
- the system is leaky.
- FIG. 3 shows the experimental timeline for the experiments described in this example.
- Induction consists of four
- Rats are allowed to recover from rapamycin for a rotational response to 5 mg/kg L-dopa. Rats are allowed to recover from rapamycin for
- Rats are induced a second time on day 31
- the agonist is dopamine synthesized from exogenous L-dopa, in the
- rapamycin group show a robust contralateral turning response to L-dopa (5 mg/kg) that is
- (+) rapamycin group (P ⁇ 0.001).
- the vector-infused (+) rapamycin group is not
- the vector-infused (-) rapamycin and the excipient-infused control groups are not significantly different at any of the time points (P > 0.05). Without intending to be bound by
- control groups may be due to sensitization to repeated L-dopa treatment.
- time points, weeks 4 and 6 is not significantly different from the vector-infused (-) rapamycin
- infused groups are transduced with equivalent numbers of copies of hAADC gene.
- hAADC expression levels are evaluated by immunohistochemical analysis at seven
- FIG. 5 A representative animal from the vector-infused (+) rapamycin group is shown in FIG. 5 A.
- FIG. 5B one from the vector-infused (-) rapamycin group is shown at FIG. 5B. As illustrated in
- FIG. 5 A hAADC transgene expression is localized to the medium spiny neurons in the rat
- FIG. 5B shows low magnification images of AADC immunohistochemistry in whole
- the left hemisphere is the site of
- 6-OHDA lesioning causes depletion of the endogenous AADC, resulting in low
- Rats all exhibit hAADC transgene staining on the infused left side (see, e.g., FIG. 6A). Rats
- rapamycin dosing is evaluated and quantitated by stereology in
- n is the number of hemispheres examined.
- Average anterior-to-posterior spread, volumes of spread, and positive cell numbers for the rapamycin-induced group are statistically different from the values for the "no induction" group (PO.02) by Student's t-tests.
- Table 1 also presents the average population of transgene positive cells and the
- the vector-infused (+) rapamycin group has the
- hAADC created per cell may differ between groups.
- hAADC expression in the uninduced group seen by immunostaining correlates with a lower
- total protein is extracted from serial tissue sections and
- ⁇ -Actin is included as a loading control.
- AADC band density is significantly higher in the vector-
- CED convection-enhanced delivery
- Vector is delivered with a programmable pump (Bioanalytical Systems, hie, West Lafayette,
- the cannula consisting of a fused silica capillary (OD, 164 ⁇ m; ID, 100 ⁇ m; Polymicro
- the target sites and cannulas are inserted vertically into the caudate-putamen at the following
- contralateral and ipsilateral turns are computed over 30 min (for apomorphine) and over 60
- L-dopa response is evaluated before surgery and at different time points (3, 4, 5, 6, and 7
- animals are perfused through the aorta with saline, followed
- rapamycin groups and n 8 rats for the vector-infused (+) rapamycin group). Brains are
- Brains are cut serially into 40- ⁇ m thick coronal sections on a cryostat.
- Sections are incubated in 3% hydrogen peroxide for 30 min to quench
- n is the number of sections with hAADC positive cells, 40 ⁇ m is the
- the vector AAV-Z12-hAADC used in this study contains the human AADC target
- the plasmid is linearized with a
- hAADC gene copies is calculated by comparison to the standard curve, and multiplying the
- Proteinase inhibitors Protein is quantified using the Bradford method. Protein samples (15
- the filters are blocked with 3% milk and incubated for 1 hr with a polyclonal rabbit
- the anti-AADC primary antibody has
- Mammalian cells are transduced with a dimerizer-regulatable GDNF transgene
- FIGS. 8 A and 8B are diagrams of recombinant AAV vector plasmid constructs for
- hGDNF regulatable human GDNF
- pAAV-CMV-hGDNF constitutively expressed hGDNF
- the regulatable constructs involve a single rAAV vector carrying
- hGDNF is driven by a minimal IL-2 promoter adjacent to eight binding sites for the dimerizable transcription factor described in greater detail below.
- a CMV construct illustrated at FIG. 8A ⁇ AAV-TF-Z8-hGDNF
- enhancer/promoter drives expression a single transcript encoding both the activation and
- an SV40 promoter drives
- the activation domain on a different transcript, from the opposite strand (i.e. in the opposite
- the DNA binding domain fusion protein contains two DNA binding domains from
- the activation domain fusion protein contains the rapamycin binding domain of
- Min hGH pA hormone polyadenylation
- control vector pAAV-CMV-hGDNF (FIG. 8C) the CMV promoter/enhancer drives
- polyadenylation (pA) sequences are indicated.
- GDNF expression is presented as a function of vector construct and rapamycin concentration.
- pAAV-TF-Z8-hGDNF directs production of GDNF in a dose-responsive manner when cells are treated with rapamycin, whereas pAAV-CMV-hGDNF directs constitutive (high) level
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des vecteurs du virus adéno-associé recombinant (rAAV) pour l'administration de transgènes régulables dans le système nerveux central (SNC) d'un mammifère. L'invention concerne également des méthodes de traitement de sujets présentant des troubles neurodégénératifs au moyen de ces vecteurs, ainsi que des trousses destinées à construire ou utiliser ces vecteurs ou à mettre en oeuvre lesdites méthodes. Des séquences transgéniques sont exprimées à partir d'une région promotrice/activatrice comprenant un ou plusieurs sites de liaison pour un facteur de transcription sensible à un inducteur moléculaire de petite taille. La construction transgénique et une construction comprenant le facteur de transcription sont administrées dans les cellules cibles. Le transgène régulable peut être administré sur le même vecteur rAAV que le facteur de transcription ou sur un vecteur séparé. Le facteur de transcription peut comprendre deux chaînes polypeptidiques, telles qu'un domaine de liaison à l'ADN et un domaine d'activation de transcription, qui forment un dimère actif en présence d'un agent de dimérisation tel que la rapamycine ou un analogue non immunogène correspondant. Les vecteurs, les méthodes et les trousses de l'invention peuvent être utilisés pour administrer des gènes tels que GDNF ou AADC dans le cerveau d'un sujet présentant un trouble neurodégénératif tel que la maladie de Parkinson, l'expression de GDNF ou AADC dans le cerveau pouvant ensuite être régulée par traitement du sujet avec de la rapamycine ou un analogue de rapamycine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63535604P | 2004-12-09 | 2004-12-09 | |
PCT/US2005/044654 WO2006063247A2 (fr) | 2004-12-09 | 2005-12-09 | Expression regulee de transgenes dans le systeme nerveux central de mammiferes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1833975A2 true EP1833975A2 (fr) | 2007-09-19 |
Family
ID=36190671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05849656A Withdrawn EP1833975A2 (fr) | 2004-12-09 | 2005-12-09 | Expression regulee de transgenes dans le systeme nerveux central de mammiferes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1833975A2 (fr) |
JP (1) | JP2008523093A (fr) |
CN (1) | CN101213305A (fr) |
IL (1) | IL183580A0 (fr) |
MX (1) | MX2007006807A (fr) |
WO (1) | WO2006063247A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
CN104232686A (zh) * | 2014-08-20 | 2014-12-24 | 江苏大学 | 小鼠维甲酸相关的孤核受体α腺相关病毒载体 |
BR112017007737A2 (pt) | 2014-10-21 | 2018-01-30 | Univ Massachusetts | variantes de aav recombinantes e usos das mesmas |
CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
EP3368054A4 (fr) | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | Expression régulable au moyen d'un virus adéno-associé (vaa) |
EP3831281A1 (fr) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Procédés de ciblage et d'administration biomédicaux, et dispositifs et systèmes pour leur mise en uvre |
KR20190075964A (ko) | 2016-10-13 | 2019-07-01 | 유니버시티 오브 매사추세츠 | Aav 캡시드 설계 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
CN118252953A (zh) * | 2022-12-26 | 2024-06-28 | 科辉智药(深圳)新药研究中心有限公司 | 一种用于神经退行性疾病治疗的基因序列构建体及其应用 |
-
2005
- 2005-12-09 WO PCT/US2005/044654 patent/WO2006063247A2/fr active Application Filing
- 2005-12-09 JP JP2007545670A patent/JP2008523093A/ja not_active Withdrawn
- 2005-12-09 EP EP05849656A patent/EP1833975A2/fr not_active Withdrawn
- 2005-12-09 CN CNA2005800424559A patent/CN101213305A/zh active Pending
- 2005-12-09 MX MX2007006807A patent/MX2007006807A/es not_active Application Discontinuation
-
2007
- 2007-05-31 IL IL183580A patent/IL183580A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2006063247A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006063247A3 (fr) | 2006-08-03 |
CN101213305A (zh) | 2008-07-02 |
JP2008523093A (ja) | 2008-07-03 |
MX2007006807A (es) | 2007-11-15 |
IL183580A0 (en) | 2007-09-20 |
WO2006063247A2 (fr) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1833975A2 (fr) | Expression regulee de transgenes dans le systeme nerveux central de mammiferes | |
US11951183B2 (en) | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof | |
US7811814B2 (en) | Tetracycline-regulated adeno-associated viral (AAV) vectors for gene delivery to the nervous system | |
US6503888B1 (en) | AAV-mediated delivery of DNA to cells of the nervous system | |
US7588757B2 (en) | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions | |
EP1299126B1 (fr) | Systemes d'administration a base d'acide glutamique decarboxylase | |
JP7433360B2 (ja) | Pah遺伝子移入のためのアデノ随伴ウイルス組成物及びそれらの使用方法 | |
CN113302201A (zh) | 重组病毒载体和用于产生所述重组病毒载体的核酸 | |
AU2022213262A1 (en) | Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy | |
US20220118107A1 (en) | Txnip and ldhb compositions and methods for the treatment of degenerative ocular diseases | |
EP3516052B1 (fr) | Gène dgkk recombinant pour thérapie génique du syndrome x-fragile | |
AU758530B2 (en) | Delivery of multiple genes to cells using plural adeno-associated viral vectors | |
BR102020023425A2 (pt) | Vetor biológico para tratamento de doenças neurodegenerativas com base em terapia gênica | |
CA3228916A1 (fr) | Compositions et methodes de traitement ameliore de troubles affectant le systeme nerveux central | |
WO2024079658A1 (fr) | Thérapie génique avec le bdnf | |
CN115135347A (zh) | 治疗帕金森病的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070706 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20080519 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081202 |